In Vitro Antioxidant and In Vivo Hypolipidemic Effects of the King Oyster Culinary-Medicinal Mushroom, Pleurotus eryngii var. ferulae DDL01 (Agaricomycetes), in Rats with High-Fat Diet-Induced Fatty Liver and Hyperlipidemia

Int J Med Mushrooms. 2017;19(2):107-119. doi: 10.1615/IntJMedMushrooms.v19.i2.20.


We investigated the effect of the culinary-medicinal mushroom Pleurotus eryngii var. ferulae DDL01 on oxidative damage in the liver and brain and a high-fat/high-cholesterol-induced hyperlipidemic model. In in vitro studies, the water extracts of the fruiting bodies showed strong scavenging activities of DPPH (139.46 ± 3.2 μg) and hydroxyl (139.46 ± 3.2 μg) radicals. Moreover, the extracts showed Fe2+ chelating and reducing abilities, as well as a large amount of polyphenols and an inhibitory effect on lipid peroxidation in the liver and brain tissues. The rats were fed a pellet diet (7.5 g/rat/day) containing P. eryngii var. ferulae DDL01 (PD) for 3 weeks. In the high-fat/high-cholesterol-induced hyperlipidemic rat model, administration of PD caused a significant decrease (P < 0.05) in the levels of serum triacylglycerols, low-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, aspartate aminotransferase, and alanine aminotransferase and a significant increase (P < 0.05) in the level of high-density lipoprotein cholesterol. PD administration significantly decreased high-fat/high-cholesterol-induced hepatic lipid accumulation. Treatment with the extracts (up to 500 μg/mL) did not significantly affect the viability of HepG2 and 3T3-L1 cells. Our findings suggest that this mushroom has potential as an antiatherogenic dietary source in the development of therapeutic agents and functional foods.

MeSH terms

  • Agaricales / chemistry
  • Alanine Transaminase / blood
  • Animals
  • Antioxidants / isolation & purification
  • Antioxidants / pharmacology*
  • Aspartate Aminotransferases / blood
  • Biphenyl Compounds / metabolism
  • Cell Line
  • Cell Survival / drug effects
  • Diet, High-Fat
  • Disease Models, Animal
  • Fatty Liver / drug therapy*
  • Hepatocytes / drug effects
  • Humans
  • Hydroxyl Radical / metabolism
  • Hyperlipidemias / drug therapy*
  • Hypolipidemic Agents / administration & dosage*
  • Hypolipidemic Agents / isolation & purification
  • Hypolipidemic Agents / pharmacology*
  • Lipoproteins / blood
  • Picrates / metabolism
  • Pleurotus / chemistry*
  • Rats
  • Treatment Outcome
  • Triglycerides / blood


  • Antioxidants
  • Biphenyl Compounds
  • Hypolipidemic Agents
  • Lipoproteins
  • Picrates
  • Triglycerides
  • Hydroxyl Radical
  • 1,1-diphenyl-2-picrylhydrazyl
  • Aspartate Aminotransferases
  • Alanine Transaminase